Agennix appoints VP of clinical development
This article was originally published in Scrip
Agennix (Germany/US) has appointed Dr Steven Simonson to the newly created position of vice-president, clinical development. He will lead the company's sepsis development programme with oral talactoferrin, which is currently in Phase III clinical trials in non-small cell lung cancer. Dr. Simonson, who has 15 years' pharmaceutical industry experience, previously held several senior positions at AstraZeneca, most recently as senior director, clinical research, infection therapeutic area.